ArticleFrontiers in endocrinology2026
Posterior minimal extrathyroidal extension as an independent risk factor for lateral lymph node metastasis in papillary thyroid carcinoma: a retrospective study based on a nomogram prediction model.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extrathyroidal extension (ETE) is a risk factor for lateral lymph node metastasis (LLNM) in patients with papillary thyroid carcinoma (PTC). However, the different effects of posterior minimal extrathyroidal extension (post-mETE) and anterior minimal extrathyroidal extension (ant-mETE) on LLNM remain unclear. This research aimed to investigate the influence of post-mETE and ant-mETE on LLNM and develop a nomogram to guide perioperative management in PTC patients at high risk for LLNM. Methods: This retrospective study included consecutive PTC patients treated from December 2017 to March 2025. The identification of clinical and pathological predictive factors for LLNM was conducted using both univariate and multivariate analytical methods, and statistically significant variables were included to construct a predictive nomogram, followed by internal validation. Results: Among 1798 patients with PTC, 391 cases (21.75%) were pathologically confirmed to have LLNM. Compared to ant-mETE, post-mETE was significantly associated with a higher incidence of LLNM (p<0.001). The results of the multivariate analysis showed that there were 6 independent predictive factors for LLNM: maximum tumor diameter >1 cm (OR = 3.022), bilateral thyroid involvement (OR = 2.198), multifocality of the tumor (OR = 1.374), number of central lymph node metastases ≥2 (OR = 8.083), tumor located at the upper pole (OR = 2.679), and post-mETE (OR = 2.036). The nomogram constructed in this study demonstrated good discrimination performance (AUC = 0.850) and clinical applicability. Conclusion: Compared to ant-mETE, PTC patients with post-mETE were more likely to develop LLNM. The predictive nomogram demonstrated high accuracy in forecasting LLNM and facilitated the identification of occult lymph node metastases. This capability assisted in determining the need for adjuvant radioactive iodine therapy or stricter follow-up management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.